{"id":"placebo-to-match-tolebrutinib","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4650323","moleculeType":"Small molecule","molecularWeight":"455.52"},"_fixedAt":"2026-03-30T12:43:59.292830","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo comparators in clinical trials are inert formulations manufactured to be indistinguishable from the active drug in Phase 3 studies. They contain no active pharmaceutical ingredient and serve as the control arm to assess the true efficacy and safety of the investigational agent relative to no pharmacological intervention.","oneSentence":"This is a placebo formulation designed to match the appearance, taste, and administration characteristics of Tolebrutinib for blinded clinical trial purposes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:46.415Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"_fixedFields":["modality→Small Molecule"],"trialDetails":[{"nctId":"NCT04458051","phase":"PHASE3","title":"Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-08-13","conditions":"Primary Progressive Multiple Sclerosis","enrollment":767},{"nctId":"NCT05132569","phase":"PHASE3","title":"Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis","status":"TERMINATED","sponsor":"Sanofi","startDate":"2021-12-03","conditions":"Myasthenia Gravis","enrollment":6},{"nctId":"NCT04411641","phase":"PHASE3","title":"Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-09-24","conditions":"Non-relapsing Secondary Progressive Multiple Sclerosis","enrollment":1131},{"nctId":"NCT04410991","phase":"PHASE3","title":"Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-06-11","conditions":"Relapsing Multiple Sclerosis","enrollment":899},{"nctId":"NCT04410978","phase":"PHASE3","title":"Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-06-30","conditions":"Relapsing Multiple Sclerosis","enrollment":974}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to match Tolebrutinib","genericName":"Placebo to match Tolebrutinib","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}